Free Republic

Regeneron Halts Enrollment of Critically Ill Patients in COVID-19 Antibody TrialRegeneron Pharmaceuticals has decided to halt enrollment of very sick patients with COVID-19 in its trial studying antibody cocktail REGN-COV2... The decision to halt critically ill patients was made in response to Regeneron’s independent safety board finding a potential safety signal and an unfavorable risk-benefit profile of the monoclonal antibody therapy in a subgroup of patients requiring high-flow oxygen or mechanical ventilation. These patients are generally sicker and hospitalized because they are in the advanced stages of the disease. The Tarrytown, N.Y.-based pharmaceutical company says it is blinded to the...

When President Trump emerged from Walter Reed Medical Center, he seemed pretty convinced that the treatment he was given was a cure for COVID-19. He reported feeling better almost immediately after being given Regeneron, a polyclonal antibody formula. Yesterday, Regeneron published the results of the first three phases of their trials for treating COVID-19. Regeneron has completed the required randomized, double-blind studies that Dr. Fauci insisted on. At the end of September, the company reported that the treatment reduced viral levels in a study of 275 patients who had no evidence of an immune response before receiving the therapy: “After...